publication venue for
- Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. 19:226-243. 2023
- Developing an Ethnographic Community‐Based Participatory Research Dementia Study with Diverse Indigenous Populations: Indigenous Cultural understandings of Alzheimer’s disease and related dementias – Research and Engagement (ICARE) project. 18. 2022
- Gonadal Hormones Contribute to Sex Differences in Autoimmunity, Pathology and Behaviour in the 3×Tg‐AD Mouse Model of Alzheimer’s Disease. 18. 2022
- Impact of a web‐based psychoeducational intervention on carer mental health quality of life: Results from a pragmatic randomized control trial. 18. 2022
- Indigenous cultural understandings of Alzheimer’s disease and related dementias – research and engagement (ICARE): relationships between cultural strengths, education and stigma. 18. 2022
- What does it take to get a diagnosis? Dementia recognition and diagnosis pathways among Indigenous peoples. 18. 2022
- Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET 2022
- Amyloid‐independent vascular contributions to cortical atrophy and cognition in a multi‐center mixed cohort with low to severe small vessel disease. 17. 2021
- Development of an indigenous functional assessment (IFA) tool. 17:e054666. 2021
- Driving and dementia: An “emotionally‐charged” issue for people with dementia and their multidisciplinary healthcare providers. 17:e051843. 2021
- Impact of COVID‐19 on family care partners of persons with dementia in long‐term care settings in Canada: Not a ‘one‐size‐fits‐all’ story. 17:e052186. 2021
- Mechanisms of neurodegeneration: How oxidative stress reduces proNGF axonal transport in basal forebrain cholinergic neurons. 17:e052362. 2021
- Polygenic risk score for Alzheimer’s disease in Caribbean Hispanics. 17:e055031. 2021
- Polymorphisms in EPHX2 and CYP2J2 moderate associations between white matter hyperintensities and temporal lobe atrophy. 17:e055592. 2021
- Traditional healing and medicine in dementia care for indigenous populations in North America, Australia, and New Zealand: A scoping review protocol. 17:e051066. 2021
- Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. 17:255-270. 2021
- Acceptability of a mental health care pathway to address dementia risk factors in primary care settings: A qualitative study. 16. 2020
- Adaptation of the Canadian indigenous cognitive assessment in three provinces and evidence for validity. 16. 2020
- Classification accuracy of the English version of the Canadian Indigenous Cognitive Assessment (CICA) in a majority culture memory clinic sample. 16. 2020
- Cognitive impairment among community‐dwelling, off‐reserve indigenous populations in Canada. 16. 2020
- Exploring opportunities for the integration of traditional healing medicine in the care and prevention of dementia for first nations people from the Wiikwemikoong Unceded Territory on Manitoulin Island in Northern Ontario, Canada. 16. 2020
- Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. 16:1182-1195. 2020
- A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank. 16:726-733. 2020
- O5‐08‐03: TRAJECTORIES OF HEALTH SYSTEM USE AND SURVIVAL FOR COMMUNITY‐DWELLING PERSONS WITH DEMENTIA: AN INCEPTION COHORT STUDY. 15:p1635-p1636. 2019
- Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. 14:280-292. 2018
- [P2–457]: SIGNS OF EARLY COGNITIVE DECLINE WITHIN CONNECTED SPEECH: EVIDENCE FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION (WRAP). 13:p812-p814. 2017
- [P2–530]: DEMENTIA AMONG COMMUNITY‐DWELLING, OFF‐RESERVE INDIGENOUS POPULATIONS IN ONTARIO. 13:p845-p845. 2017
- The Vascular Impairment of Cognition Classification Consensus Study. 13:624-633. 2017
- O3‐10‐04: Adapting the Kimberly Indigenous Cognitive Assessment for Use with Indigenous Older Adults in Canada. 12:p311-p311. 2016
- P2‐301: Characteristics of Connected Language Subtypes in the Wisconsin Registry for Alzheimer's Prevention. 12:p749-p751. 2016
- P3‐388: Trends in Health System use by Persons with Dementia in Ontario from 2007 and 2013: A Population‐Based Study. 12:p997-p998. 2016
- Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage. 11:1480-1488. 2015
- IC‐P‐004: The association between amyloid burden and language outcomes in the wisconsin registry for Alzheimer's prevention (WRAP). 11:p14-p15. 2015
- O2‐07‐06: The effects of computerized cognitive testing of older patients on primary care physicians' care strategies. 11:p190-p191. 2015
- P4‐124: The association between amyloid burden and language outcomes in the wisconsin registry for Alzheimer's prevention (WRAP). 11:p825-p826. 2015
- P2‐325: A COMPARISON OF HEALTH UTILITY SCORES CALCULATED USING UNITED KINGDOM AND CANADIAN PREFERENCE WEIGHTS IN AN ALZHEIMER'S DISEASE SAMPLE. 10:p598-p598. 2014
- P3‐091: PLASMA AMYLIN LEVELS ARE ASSOCIATED WITH BRAIN STRUCTURE AMONG INDIVIDUALS WITH TYPE‐2 DIABETES. 10:p661-p661. 2014
- P3‐304: FALLS IN COMMUNITY‐DWELLING OLDER ADULTS WITH EARLY MEMORY PROBLEMS. 10:p742-p742. 2014
- P3‐305: CHARACTERISTICS OF FALLS IN COMMUNITY‐DWELLING OLDER ADULTS WITH EARLY MEMORY PROBLEMS. 10:p742-p743. 2014
- Does the evidence say a 4‐point change in ADAS‐cog score is clinically significant?. 10:416-417. 2014
- O2–05–01: The social experiences of spouses of persons with young‐onset dementia (YOD): Social change, support and resiliency. 9:p324-p324. 2013
- P1–251: 25‐Hydroxyvitamin D, cognition and Alzheimer's disease. 9:p244-p244. 2013
- P3‐297: Rural Dementia Action Research (RaDAR) team: Report on a community‐based primary health care team grant planning session. 8:p563-p563. 2012
- P3‐312: The association between caregiver and patient health‐related quality‐of‐life in Alzheimer's disease. 8:p568-p569. 2012
- P3‐407: Patients’ and caregivers’ willingness to pay for a new Alzheimer's disease medication. 7:s645-s646. 2011
- Commentary on “Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” A Canadian perspective. 7:330-332. 2011
- O1‐01‐05: Brain microvascular fragility is a major cause of Alzheimer's disease. 5:p77-p78. 2009
- P1‐208: How does the Canadian general public view moderate Alzheimer's disease? determination of health utility scores. 5:p238-p238. 2009
- P1‐222: Canadians’ willingness to pay for Alzheimer's disease medications: Preliminary results of a study of the general public. 5:p241-p241. 2009
- P2‐226: Public support for an annual tax increase to provide access to an Alzheimer's disease medication in Canada. 5:p326-p327. 2009
- P2‐287: The impact of clinician judgment on the decision to insure a medication for Alzheimer's disease. 4:t456-t456. 2008
- P3‐438: The role of clinician judgment in Canadian formulary committee members' recommendations to insure an Alzheimer's disease medication: Results of a pilot qualitative study. 4:t650-t650. 2008
- General risk factors for dementia: A systematic evidence review. 3:341-347. 2007
- Primary prevention of dementia. 3:348-354. 2007
- P2–330: Altered brain iron metabolism as a risk factor for Alzheimer's disease. 2:s338-s338. 2006
- The reciprocal risks of stroke and cognitive impairment in an elderly population. 2:171-178. 2006
- Leveraging amino acid sensors as therapeutic targets for tauopathies and related dementias 2020
- P4-499: THE RETROGRADE TRANSPORT OF BDNF AND PRONGF DIMINISHES WITH AGE IN BASAL FOREBRAIN CHOLINERGIC NEURONS 2019
- [O1–14–05]: SEX‐SPECIFIC CHANGES IN SYSTEMIC IMMUNE STATUS AND CENTRAL PATHOLOGY IN 3XTG‐AD MICE 2017
- [P1–209]: NGF AND BDNF DYSMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE 2017
- P4‐086: TAU Modulates BDNF Expression and Mediates Aβ‐Induced Bdnf Down‐Regulation in Animal and Cellular Models of Alzheimer's Disease 2016
- P3‐189: BDNF downregulation in post mortem brain tissue of subjects with tauopathies 2009
- P1‐345: BDNF mRNA levels are decreased in peripheral blood samples from subjects with Alzheimer's disease 2008
- P1–032: Decreased BDNF mRNA levels in mouse models of Alzheimer's disease 2006